Clinical Trials Logo
  1. Home
  2. Metastatic Lung Cancer
  3. NCT05609578

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

Metastatic Lung Cancer Clinical Trial

Official title:
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Clinical Trial Summary

Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS <50% and KRAS G12C mutation

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05609578
Study type Interventional
Source Mirati Therapeutics Inc.
Contact Mirati Therapeutics Study Locator Services
Phone 18448935530
Email miratistudylocator@careboxhealth.com
Status Recruiting
Phase Phase 2
Start date July 29, 2022
Completion date December 1, 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Recruiting NCT05846594 - A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer Phase 4
Not yet recruiting NCT03514329 - Vapor Ablation for Localized Cancer Lesions N/A
Recruiting NCT05502913 - Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer Phase 2
Recruiting NCT06060613 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Completed NCT01543672 - Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously Phase 1/Phase 2
Completed NCT03198468 - Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE) N/A
Recruiting NCT06180460 - CALM: Managing Distress in Malignant Brain Cancer N/A
Completed NCT04804137 - Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study
Recruiting NCT04940325 - Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer Phase 2
Active, not recruiting NCT05241873 - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Recruiting NCT05256290 - Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations Phase 1/Phase 2
Completed NCT05908799 - Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Active, not recruiting NCT03867175 - Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer Phase 3
Recruiting NCT04708483 - DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria N/A
Completed NCT01307501 - Safety and Efficacy of Cryoablation for Metastatic Lung Tumors N/A
Recruiting NCT03143322 - Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases N/A
Recruiting NCT05143970 - A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT03415126 - A Study of ASN007 in Patients With Advanced Solid Tumors Phase 1